SNAP Trial Data Co-ordinator - University of Newcastle

FullTimeFixedTerm • New Lambton Heights NSW 2305, Australia • Contribute to a high-impact trial by ensuring data is accurate, reliable, and ready to inform critical research findings

livehire.com

helancet.com

Communicable E52: ESCMID Global Trials, PETER PEN and ASTARTE | Communicable | Episode 52

In this collaborative episode of Breakpoints and Communicable, the hosts revisit the “trial run” session from ESCMID Global, a format designed to facilitate critical discussion of major infectious dis...

share.transistor.fm

A simple daily routine could cut hospital pneumonia rates

Regular oral hygiene could reduce hospital pneumonia risk by up to 60%, according to a new study.

euronews.com

$5 million boost for world-first trial tackling strep infections in both children and adults - Doherty Institute

A major new clinical trial, the Streptococcal Adaptive Platform (STRAP), has received $5 million in funding from the Australian Government’s Medical Research Future Fund (MRFF) to improve treatment for life-threatening streptococcal infections across all age groups. Lead by researchers and clinicians from the Doherty Institute, Murdoch Children's Research Institute (MCRI), and other national and international partners.

doherty.edu.au

More than a message: Death by a 1,000 “Chats”

Abstract. Secure electronic messaging within the electronic health record (EHR), such as Epic Chat, has transformed communication in hospitals by enabling

doi.org

How Do We Win? The GAME CHANGER Trial

Erin K. McCreary, PharmD (1), Ahmad Mourad, MD MHS (2, 3)

clarityinitiative.org

The Pandemic Respiratory Virus Epidemiological Surveillance Trial - A Self-swab Surveillance System for Respiratory Viruses Nested Within FluTracking

PREVENT aimed to evaluate the feasibility of a community self-swab respiratory surveillance system embedded within the FluTracking Australia Framework. Hig

academic.oup.com

Safety, tolerability, and pharmacokinetics of a 2 g subcutaneous dose of ceftriaxone as an alternative to intravenous delivery

ABSTRACTSubcutaneous delivery of antibiotics is a practical alternative to intravenous administration. Ceftriaxone is commonly used for a variety of infections with limited data on the safety and pharmacokinetics of a 2 g subcutaneous dose. This was a prospective, self-controlled cross-over study in 20 stable inpatients receiving ceftriaxone for their infection. Following an intravenous dose, participants received a single dose of 2 g subcutaneous ceftriaxone, in 50 mL normal saline via gravity feed. Capillary dried blood spots were collected at baseline, 1, 2, 4, 8, and 24 hours following the subcutaneous and intravenous doses. Pain scores and infusion site reactions (edema/erythema) were assessed. Ceftriaxone concentrations were measured using a validated liquid chromatography-tandem mass spectrometry assay. A population pharmacokinetic model was developed using nonlinear mixed-effects modeling. The highest median (interquartile range) pain score within the first 2 hours following infusion of a subcutaneous dose of 2 g ceftriaxone was 2.5 (1–4). All participants were pain-free 4 hours after the infusion. The estimated bioavailability was 95.7% (95% bootstrap interval 90.3–99.5). Compared with intravenous, subcutaneous administration resulted in lower peak and comparable trough concentrations. The probability of target attainment for free drug concentrations was similar to intravenous administration for most common infections in hospitalized patients. Subcutaneous administration of 2 g ceftriaxone is well tolerated and has a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.IMPORTANCEThis prospective, self-controlled cross-over design study demonstrates that subcutaneous administration of 2 g ceftriaxone appears safe and well tolerated with a comparable pharmacokinetic profile relative to intravenous dosing in non-critically ill patients with severe infections.CLINICAL TRIALSThis study was registered at ACTRN12624000692538.

journals.asm.org

The CLARITY initiative: Clinical Literature Appraisal and Research education in InfecTious diseases and microbiologY

Over the past two decades, the generation and application of clinical evidence in the fields of clinical infectious diseases and microbiology have entered a new era: one in which clinical guidelines a...

cmi-comms.org

cdc.gov.au

sciencedirect.com

Making sense of hierarchical composite endpoints in randomized clinical trials – a primer for infectious disease clinicians and researchers

Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,

doi.org

Communicable E28: Late-breaker trials at ESCMID Global: Should they change your practice? - part 2

Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald...

share.transistor.fm

Communicable E27: Late-breaker trials at ESCMID Global: Should they change your practice? - part 1

This episode of Communicable takes on a special format where editors of...

share.transistor.fm